自動化和封閉式細胞治療處理系統市場－全球產業規模、佔有率、趨勢、機會、預測：按工作流程、類型、規模、地區和競爭格局分類，2021-2031年

全球自動化閉式細胞治療處理系統市場預計將從 2025 年的 9.3108 億美元成長到 2031 年的 15.9359 億美元，複合年成長率達到 9.37%。

這些系統作為一個整合平台，可在密封環境中分離、濃縮、培養和收穫治療性細胞，有效降低污染風險並減少人工干預。推動該市場發展的關鍵因素包括：為滿足日益成長的先進治療方法需求，迫切需要可擴展的生產解決方案；以及符合良好生產規範 (GMP) 的嚴格監管要求。根據美國基因與細胞治療學會 (ASGCT) 預測，到 2024 年，全球將有超過 4000 種基於基因、細胞和 RNA 的治療方法處於研發階段，這凸顯了高效加工技術對於支持這一龐大臨床研發管線的重要性。

然而，該市場面臨許多挑戰，因為實施這些系統需要大量的資本投入，而中小企業往往難以承擔向全自動化工作流程轉型所需的成本。此外，這些系統的技術複雜性也構成了進入門檻，需要高度專業化的人員才能有效地運作和維護這些基礎設施。

市場促進因素

全球細胞和基因療法研發管線的快速擴張，正大幅推動自動化閉迴路處理系統的應用。隨著製藥公司將候選藥物從研發階段推進到後期臨床試驗和商業化生產階段，對能夠確保無菌性和擴充性的設施的需求也隨之激增。根據再生醫學聯盟的數據，截至2024年1月，全球約有1900項臨床試驗正在進行，顯示大量潛在治療方法需要標準化的生產基礎設施。這種研發管線的擴張與商業性現實直接相關，因此迫切需要能夠在不影響品質的前提下支援高通量生產的平台。根據《細胞與基因療法評論》報道，截至2024年11月，美國FDA已核准了7種新的細胞和基因療法，這一趨勢凸顯了市場向商業化可行的自動化處理解決方案轉變的重要性。

同時，由於迫切需要降低生產和營運成本，製藥業正被迫摒棄勞力密集的手工工作流程。傳統的開放式生產方法高度依賴熟練的操作人員，並且需要大規模無塵室設施，因此成本極為高。自動化封閉式系統透過顯著降低銷貨成本和提高批次一致性，消除了這些經濟瓶頸。據 Cellares 公司稱，截至 2024 年 3 月，其符合 cGMP 標準的自動化生產平台與傳統的手動流程相比，已將人事費用和設施規模需求降低了 90%。透過最大限度地減少人為干預和面積，這些系統使製造商能夠實現滿足全球日益成長的患者需求所需的擴充性和經濟可行性。

市場挑戰

自動化閉迴路細胞治療處理系統的實施需要大量的資本投入，這成為市場擴張的主要障礙。這些整合平台需要大量的初期投資，不僅包括設備成本，還包括設施整合和合格費用。對於通常引領該領域創新的中小企業而言，這種財務負擔可能構成障礙。因此，許多潛在用戶被迫依賴成本較低的人工處理方法，這限制了自動化解決方案的即時基本客群，並減緩了市場滲透的整體速度。

鑑於產業現狀，這些資金限制尤為嚴峻。根據再生醫學聯盟統計，截至2024年，全球整體約有3,000家研發營業單位從事該領域的工作。其中大多數是資金有限的新興生技公司，難以承擔向昂貴的自動化基礎設施轉型所帶來的成本。這一關鍵領域無法採用先進的加工系統，直接限制了製造商的銷售量。此外，大型企業嚴格的資本核准流程也減緩了技術的普及，阻礙了市場的發展。

市場趨勢

合約研發生產機構 (CDMO) 對自動化平台的策略性採用，標誌著市場商業結構的根本性轉變。 CDMO 正在增加對多功能封閉式系統技術的投資，以確保從領先的製藥研發公司獲得長期產能，從而實現不同治療方法方式的標準化生產。這一趨勢正引領產業走向一種新的模式：產能不再完全依賴內部建設，而是可以透過第三方合作夥伴靈活快速地擴展。據 Cellares 公司稱，該公司於 2024 年 4 月與百時美施貴寶公司簽署了一項價值高達 3.8 億美元的全球產能預訂和供應協議，使用其自動化平台 Cell Shuttle 生產 CAR-T 細胞療法。

同時，為了因應個人化醫療在物流方面的複雜性，分散式和照護現場生產模式正日益受到關注。透過將處理系統直接整合到醫院和臨床中心，相關人員旨在顯著縮短從靜脈到靜脈的運輸時間，並消除長途冷凍保存運輸帶來的風險。這種生產能力的在地化將治療中心轉變為生產樞紐，使患者能夠立即獲得新鮮的細胞產品。據MD安德森癌症中心稱，該機構於2024年11月成立了“細胞療法發現與創新研究所”，並投入超過8000萬美元的資金，以加速開發和生產對臨床實踐具有直接影響的細胞療法。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：自動化封閉式細胞治療處理系統的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 工作流程分解（分離、擴增、血漿分離、填充/精製、冷凍保存、其他）
  • 依類型（幹細胞療法、非幹細胞療法）
  • 按規模（商業化前/研發規模、商業規模）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美自動化封閉式細胞治療處理系統市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲自動化封閉式細胞治療處理系統市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區自動化封閉式細胞治療處理系統市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲自動化封閉式細胞治療處理系統的市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲自動化封閉式細胞治療處理系統的市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球自動化封閉式細胞治療處理系統市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Miltenyi Biotec BV & Co. KG
• Lonza Group AG
• Fresenius Kabi AG
• Global Life Sciences Solutions USA LLC
• BioSpherix, LLC
• Terumo Corp
• Sartorius AG
• ThermoGenesis Holdings Inc
• Cellares Corporation
• Thermo Fisher Scientific Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Automated And Closed Cell Therapy Processing Systems Market is projected to expand from USD 931.08 Million in 2025 to USD 1593.59 Million by 2031, achieving a compound annual growth rate of 9.37%. These systems function as integrated platforms designed to isolate, enrich, expand, and harvest therapeutic cells within a sealed environment, effectively minimizing contamination risks and reducing the need for manual handling. Primary drivers fueling this market include the urgent requirement for scalable manufacturing solutions to meet the rising demand for advanced therapies and the strict regulatory mandates for Good Manufacturing Practice compliance. According to the American Society of Gene & Cell Therapy, over 4,000 gene, cell, and RNA-based treatments were in research and development globally in 2024, highlighting the necessity for efficient processing technologies to support this robust clinical pipeline.

However, the market encounters a significant challenge regarding the high capital investment required for implementation, as small and medium-sized enterprises often struggle with the costs of transitioning to fully automated workflows. Furthermore, the technical complexity of these systems creates a barrier to entry, necessitating a highly specialized workforce to operate and maintain this infrastructure effectively.

Market Driver

The exponential growth in the global cell and gene therapy pipeline acts as the primary catalyst propelling the adoption of automated and closed processing systems. As pharmaceutical developers transition candidates from research settings to late-stage clinical trials and commercial production, there is a surging demand for equipment capable of ensuring sterility and scalability. Data from the Alliance for Regenerative Medicine indicates that in January 2024, there were approximately 1,900 active clinical trials globally, reflecting a massive accumulation of potential treatments requiring standardized manufacturing infrastructure. This pipeline expansion is directly translating into commercial reality, creating an urgent necessity for platforms that can support high-throughput production without compromising quality. According to the Cell & Gene Therapy Review, as of November 2024, the U.S. FDA had granted approval to seven new cell and gene therapies in 2024, a trend that underscores the critical market shift toward commercial-ready, automated processing solutions.

Simultaneously, the imperative to reduce manufacturing costs and operational overheads is driving the industry away from labor-intensive manual workflows. Traditional open processing methods are prohibitively expensive due to the high reliance on skilled operators and the need for extensive cleanroom facilities. Automated, closed systems address these economic bottlenecks by significantly lowering the cost of goods sold and enhancing batch consistency. According to Cellares, in March 2024, their cGMP-compliant automated manufacturing platform was reported to reduce labor and facility size requirements by 90% compared to conventional manual processes. By minimizing human intervention and footprint, these systems enable manufacturers to achieve the scalability and economic viability necessary to meet the growing global patient demand.

Market Challenge

The high capital investment required to implement automated and closed cell therapy processing systems acts as a significant barrier to market expansion. These integrated platforms necessitate substantial upfront expenditure, which includes the cost of the equipment as well as expenses for facility integration and qualification. For small and medium-sized enterprises, which frequently drive innovation in this sector, such financial demands can be prohibitive. Consequently, many potential adopters are forced to rely on less expensive manual processing methods, thereby limiting the immediate customer base for automated solutions and slowing the overall rate of market penetration.

This financial constraint is particularly critical given the landscape of the industry. According to the Alliance for Regenerative Medicine, in 2024, the sector encompassed approximately 3,000 developers globally. A vast majority of these entities are emerging biotechnology firms with finite financial resources, making the transition to expensive automated infrastructure difficult to justify. The inability of this substantial segment to afford advanced processing systems directly restricts sales volume for manufacturers, while the rigorous capital approval processes required by larger firms further delay implementation and hamper the market's growth trajectory.

Market Trends

The strategic adoption of automated platforms by Contract Development and Manufacturing Organizations (CDMOs) represents a fundamental shift in the market's commercial structure. CDMOs are increasingly investing in versatile, closed-system technologies to secure long-term capacity reservations from major pharmaceutical developers, thereby standardizing production across different therapeutic modalities. This trend moves the industry toward a model where manufacturing capacity is flexible and rapidly scalable through third-party partners rather than solely internal builds. According to Cellares, in April 2024, the company entered a worldwide capacity reservation and supply agreement valued at up to $380 million with Bristol Myers Squibb to manufacture CAR-T cell therapies using its automated Cell Shuttle platform.

Concurrently, the adoption of decentralized and point-of-care manufacturing models is gaining traction to address the logistical complexities of personalized treatments. By integrating processing systems directly within hospitals and clinical centers, stakeholders aim to drastically reduce vein-to-vein timelines and eliminate the risks associated with long-distance cryopreserved transport. This localization of manufacturing capability transforms treatment centers into production hubs, facilitating immediate patient access to fresh cellular products. According to MD Anderson Cancer Center, in November 2024, the institution launched its Institute for Cell Therapy Discovery & Innovation with over $80 million in funding to accelerate the development and manufacturing of impactful cell therapies directly within a clinical setting.

Key Market Players

• Miltenyi Biotec B.V. & Co. KG
• Lonza Group AG
• Fresenius Kabi AG
• Global Life Sciences Solutions USA LLC
• BioSpherix, LLC
• Terumo Corp
• Sartorius AG
• ThermoGenesis Holdings Inc
• Cellares Corporation
• Thermo Fisher Scientific Inc.

Report Scope

In this report, the Global Automated And Closed Cell Therapy Processing Systems Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Automated And Closed Cell Therapy Processing Systems Market, By Workflow

• Separation
• Expansion
• Apheresis
• Fill-Finish
• Cryopreservation
• Others

Automated And Closed Cell Therapy Processing Systems Market, By Type

• Stem Cell Therapy
• Non-Stem Cell Therapy

Automated And Closed Cell Therapy Processing Systems Market, By Scale

• Pre-commercial/ R&D Scale
• Commercial Scale

Automated And Closed Cell Therapy Processing Systems Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Automated And Closed Cell Therapy Processing Systems Market.

Available Customizations:

Global Automated And Closed Cell Therapy Processing Systems Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Automated And Closed Cell Therapy Processing Systems Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Workflow (Separation, Expansion, Apheresis, Fill-Finish, Cryopreservation, Others)
  • 5.2.2. By Type (Stem Cell Therapy, Non-Stem Cell Therapy)
  • 5.2.3. By Scale (Pre-commercial/ R&D Scale, Commercial Scale)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Automated And Closed Cell Therapy Processing Systems Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Workflow
  • 6.2.2. By Type
  • 6.2.3. By Scale
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Workflow
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Scale
  • 6.3.2. Canada Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Workflow
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Scale
  • 6.3.3. Mexico Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Workflow
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Scale

7. Europe Automated And Closed Cell Therapy Processing Systems Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Workflow
  • 7.2.2. By Type
  • 7.2.3. By Scale
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Workflow
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Scale
  • 7.3.2. France Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Workflow
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Scale
  • 7.3.3. United Kingdom Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Workflow
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Scale
  • 7.3.4. Italy Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Workflow
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Scale
  • 7.3.5. Spain Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Workflow
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Scale

8. Asia Pacific Automated And Closed Cell Therapy Processing Systems Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Workflow
  • 8.2.2. By Type
  • 8.2.3. By Scale
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Workflow
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Scale
  • 8.3.2. India Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Workflow
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Scale
  • 8.3.3. Japan Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Workflow
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Scale
  • 8.3.4. South Korea Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Workflow
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Scale
  • 8.3.5. Australia Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Workflow
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Scale

9. Middle East & Africa Automated And Closed Cell Therapy Processing Systems Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Workflow
  • 9.2.2. By Type
  • 9.2.3. By Scale
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Workflow
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Scale
  • 9.3.2. UAE Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Workflow
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Scale
  • 9.3.3. South Africa Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Workflow
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Scale

10. South America Automated And Closed Cell Therapy Processing Systems Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Workflow
  • 10.2.2. By Type
  • 10.2.3. By Scale
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Workflow
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Scale
  • 10.3.2. Colombia Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Workflow
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Scale
  • 10.3.3. Argentina Automated And Closed Cell Therapy Processing Systems Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Workflow
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Scale

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Automated And Closed Cell Therapy Processing Systems Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Miltenyi Biotec B.V. & Co. KG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza Group AG
• 15.3. Fresenius Kabi AG
• 15.4. Global Life Sciences Solutions USA LLC
• 15.5. BioSpherix, LLC
• 15.6. Terumo Corp
• 15.7. Sartorius AG
• 15.8. ThermoGenesis Holdings Inc
• 15.9. Cellares Corporation
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer